Acute Anterior Uveitis (AAU), Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA), Axial Psoriatic Arthritis (axPsA), Crohn Disease (CD), Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Ulcerative Colitis (UC)
Conditions
Brief summary
The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). GESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.
Interventions
None listed
Sponsors
German Federal Ministry of Education and Research
AbbVie
Amgen
Centocor, Inc.
Schering-Plough
Wyeth is now a wholly owned subsidiary of Pfizer
Berlin Institute of Health
Novartis
UCB Pharma
Charite University, Berlin, Germany
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
Main inclusion Criteria: * Patients with definite diagnosis of axial spondyloarthritis or juvenile spondyloarthritis. * Patients with definite diagnosis of Crohn's disease. * Patients with definite diagnosis of acute anterior uveitis. * Patients with definite diagnosis of psoriatic arthritis with axial involvement.
Countries
Germany
Contacts
Primary ContactDenis Poddubnyy, Prof. Dr.
Outcome results
None listed